FDA Will Require Early Assessment of New Targeted Agents That May Be Used in Pediatric Cancers

Web Exclusives —December 16, 2019

On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers.

The guidance document was issued in advance of original new drug applications (NDAs) and biologics license applications (BLAs) that the FDA expects to receive on or after August 18, 2020, the date that the provisions of the amendment will become effective.

Titled “FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act—Guidance for Industry,” the document is designed to provide information to pharmaceutical companies, clinical investigators, and institutional review boards ahead of planning their studies of molecularly targeted oncology drugs, with stipulations for early planning for pediatric evaluation of products that have the potential to treat this patient population.

“Specifically, if an original NDA or BLA is for a new active ingredient, and the drug that is the subject of the application is intended for treatment of an adult cancer and directed at a molecular target the FDA determines to be substantially relevant to the growth or progression of a pediatric cancer, reports on the required molecularly targeted pediatric cancer investigation must be submitted with the marketing application, unless this requirement is waived or deferred,” the FDA noted in a press release.

According to Adm. Brett P. Giroir, MD, Acting FDA Commissioner, the agency anticipates that the new amendments “will facilitate early pediatric assessment of certain targeted cancer drugs and accelerate the development of new, safe, and effective therapies for pediatric patients.”

The FDA will issue the final version of the guidance in 2020 and invites comments on the draft, preferably by February 11, 2020.

“When it comes to medical product innovation, children must always remain front-of-mind, particularly those with dire needs. It is important to deliver promising new therapies as quickly as possible, while still ensuring the utmost safety,” Dr Giroir added.

Related Articles
Creativity and Healing: Making Cancer Magic
September 2020 Vol 11, No 9
Making art and telling stories with patients can lead to profound healing, according to Sharon Chappell, PhD, breast cancer survivor, author, and educator at Cal State Fullerton.
FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications
Web Exclusives
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer
Web Exclusives
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country